Device Trial Radar · NCT04299282
CIED Implantation in Low BMI Patients
Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 2021
Primary completion
Dec 2021
Study completion Mar 2022
Sponsor
- Lead sponsor
- Elutia Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 6, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to demonstrate a better degree of healing at the incision site and a decrease in erosion with CanGaroo compared to control patients (no envelope, CIED alone).
Conditions
- Heart Diseases
- Cardiac Disease
Interventions
CanGarooDevice
CIED ECM envelope
Primary outcomes
What the sponsor says the trial is designed to measure.
- Healing at incision siteTime frame: 3 months post CIED implantation
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.